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ABSTRACT: 
To date, few studies have explored whether being 
diagnosed with cancer interrupted medication adherence 
for their non-cancer chronic conditions.35-37 This study 
examined the effect of being diagnosed with prostate 
cancer on adherence to OHAs among patients with type 
2 diabetes. Non-metastatic, lower-risk prostate cancer is 
an excellent case study for studying survivorship care 
because it is prevalent and has high survival rates; 
diabetes is important not only because of its prevalence 
but also its morbidity  and associated health care costs. 
This study hypothesized that patients would become less 
adherent to their OHAs during the first year post–
prostate cancer diagnosis compared to their pre-diagnosis 
adherence levels, however their adherence would return 
to similar rates during the second year after being 
diagnosed. This study found that patients diagnosed with 
prostate cancer did have decreased adherence when 
compared with controls in the period immediately 
following cancer-diagnosis; however, contrary to our 
hypothesis, adherence to their diabetes medications never 
returned to pre-diagnosis levels. A similar decline was 
observed among all stages of prostate cancer patients 
during the 6 months post-diagnosis.17 However, our 
current study had a longer follow-up period (2 years vs. 6 
months post– cancer diagnosis) and more years of data. 
In addition, This study only included patients with non-
metastatic prostate cancer, a group for whom managing 
comorbidities would be a higher priority than patients 
with more aggressive cancer. The finding that diabetes 
patients diagnosed with a highly survivable cancer have 
decreased adherence to their diabetes medications two 
years after diagnosis is concerning. Certainly, primary 
care physicians and oncologists should not necessarily 
assume that their patients with chronic diseases will 
return to their baseline medication adherence levels after 
completing cancer treatments, particularly when patients 
believe controlling their diabetes or other chronic 
conditions is not as necessary as it truly is. Given the 
morbidity and mortality from non-cancer chronic 
conditions, providers should actively emphasize the 
importance of taking all medications. 
Keywords: Non-metastatic prostate, type 2 
diabetes, OHAs 
Background 
An estimated 29.1 million (9.3% of the U.S. 
population) have a diagnosis of diabetes. Given the 
obesity epidemic in the United States, the 
prevalence of diabetes is rising rapidly. An 
estimated 30% to 50% will have diabetes by 
2050.1,2 Persons with diabetes are at increased risk 
of developing heart disease, stroke, blindness, end-
stage renal disease, neuropathy, lower limb 
amputations,3,4 and death.1 For patients with 
diabetes, glycemic control reduces the risk of these 
serious complications. One important aspect of 
managing diabetes is medication adherence. 
Unfortunately, adherence to diabetes medications is 
often poor, which is associated with suboptimal 
glucose control as well as all-cause hospitalization 
and mortality.8 
Given the aging of the U.S. population and the 
development of more effective cancer screening 
and treatments, the number of diabetes patients 
who are cancer survivors is growing.9 Prostate 
cancer is the most common cancer in men and 
accounts for approximately 43% of male cancer 
survivors;10 86% of men with prostate cancer are 
diagnosed with local or regional disease, and their 
5-year relative survival rate is nearly 100%.11 
Many cancer survivors, including men with 
prostate cancer, are more likely to die from co-
existing chronic conditions than from their 
cancer(s) or recurrences.12 In part, this may be 
because even when prescribed evidence-based 
guidelines for their non-cancer conditions, cancer 
survivors may be less likely to adhere to these 
recommendations than patients without 
cancer.13,14,15 A critical question is how being 
diagnosed with cancer affects adherence with 
diabetes medications. 
Being diagnosed with cancer may serve as a health 
wake-up call for patients,16 prompting them to 
become more active and engaged in their health 
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and health care, leading to higher adherence. 
However, it is also possible that medication 
adherence decreases after a cancer diagnosis 
because patients and their providers focus on 
cancer treatment and survival.17 Using early-stage 
prostate cancer as a case study, This study 
examined how adherence to diabetes medications 
changed during the two years after being diagnosed 
with cancer. This study hypothesized during the 
first year after being diagnosed with cancer, a 
period of active cancer treatment, adherence to 
diabetes medications will decrease, however 
diabetes medication adherence will return to pre– 
cancer diagnosis levels during the second year after 
being diagnosed with prostate cancer. 
Methods 
Data Sources 
This study analyzed 2007–2012 SEER 
(Surveillance, Epidemiology, and End Results)- 
Medicare data. SEER data come from population-
based cancer registries in 20 states and regions 
across the United States.18 SEER data are then 
merged with Medicare claims data that is contained 
across multiple files. The Patient Entitlement and 
Diagnosis Summary File (PEDSF) were used to 
obtain information on patient cancer diagnosis and 
treatment and patient demographics as well as 
information on patients’ Medicare Parts A and B 
enrollment. The Part D Enrollment file and Part D 
Event file were used to obtain Part D enrollment 
information as well all prescriptions and the fill 
dates with Medicare Part D. This study also 
analyzed data from a 5% random sample of fee- 
for-service Medicare enrollees without cancer; 
these data came from the Summarized 
Denominator File (SUMDENOM) to provide 
information for patients with evidence of diabetes 
but with no history of cancer. 
Cohorts 
For this retrospective study, This study restricted 
cases and controls to patients with type 2 diabetes, 
defined as having filled a prescription for an oral 
hypoglycemic agent (OHA)19 during the 2007–
2012 study period.  
In addition to having type 2 diabetes, cases had to 
meet the following criteria: (1) have a diagnosis of 
prostate cancer (ICD-O-3 code 28010) that allows 
for sufficient pre- and post-follow-up time, from 
dates January 1, 2007, through December 31, 2010; 
(2) no evidence of prior diagnosis of any cancer 
(including prostate) as far back as the SEER 
registry goes (1973), nor any subsequent cancer 
diagnosis during the study period; (3) no metastatic 
(stage IV) cancer/only Gleason Scores <7 (i.e., 
low-risk patients); (4) continuously enrolled in 
Medicare Parts A, B, and D for 33 months (9 
months prior to and 24 months after being 
diagnosed with prostate cancer); and (5) have at 
least one OHA fill during the 6 months prior to 
diagnosis.17 Additionally, to ensure that patients 
had a diabetes fill at the start of the study and to 
accurately calculate patients’ adherence during the 
entire study period, patients were required to have 
at least one OHA fill during the 3 months prior to 
the study period. 
Controls included patients identified as having type 
2 diabetes but no prostate or any other recorded 
history of cancer diagnosis in the SEER cancer 
registry. A study entry date was created to match 
controls to case patients by randomly generating a 
number between 0 and 1,275; this represented the 
time frame of potential diagnosis dates for controls 
(June 30, 2007, through January 1, 2011) that 
allowed the same 30-month observation period (6 
months before and 24 months after the pseudo 
date). Controls, like cases, were required to be 
continuously enrolled in Medicare Parts A, B, and 
D for this 30-month period as well as at least one 
OHA fill during an additional 3 months of Part D 
enrollment prior to the 30-month study period (see 
Figure 2). 
Measures 
The primary dependent variable, patients’ 
adherence to their OHA, was measured each month 
throughout the 30-month study period as the 
proportions of days covered (PDC), a widely used 
approach that uses pharmacy claims data, takes the 
days of medication supplied (numerator) divided 
by the total days (denominator) in a specified time 
interval.20,21 OHAs included sulfonylureas, 
metformin, meglitinides, thiazolidnediones, 
dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-
glucose co- transporter 2(SGLT2) inhibitors, alpha-
glucosidase inhibitors, bile acid sequestrants, and 
glucagon-like peptide-1 (GLP-1) receptor agonists 
(Appendix Table 1).22 PDC was calculated for 
each patient and each month within each OHA 
class.19 If patients switched between OHAs in the 
same class within a month or prescription period 
(generally 30 to 60 days), patients were considered 
continuously adherent without interruption. For 
patients who took multiple OHAs simultaneously, 
an overall adherence measure was calculated for 
each patient during each month/period. For each 
observation, patients were classified as adherent for 
each month if their PDC was > 80% for at least one 
of their OHAs in that month; this is consistent with 
previous studies on medication adherence. 5,8,23 
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For the primary analysis, monthly adherence was 
aggregated into five consecutive six-month 
intervals (6 months prior to diagnosis date, 
diagnosis date through 6 months, 7–12 months, 13–
18 months, and 19–24 months). Time periods and 
group (case or control) were the main independent 
variables. 
Analysis 
This study compared characteristics of men with 
and without cancer before and after being matched 
by propensity scores, using Chi-square and t-tests 
for categorical and continuous variables, 
respectively. To create propensity scores, cases and 
controls were matched on observable, independent 
characteristics that were available for both groups 
in the SEER-Medicare data. The first step was to 
examine the relationship between each 
characteristic and the likelihood of having a 
prostate cancer diagnosis. The propensity score 
model included the following variables at time of 
diagnosis: urban/rural residence,24 age, SEER 
region,25 or a combination of the latter two), 
whether or not a patient was dually eligible for 
Medicaid or received a low-income subsidy (full, 
partial, or no low-income subsidy) to help pay for 
prescriptions, and the Klabunde adaptation of the 
Charlson Comorbidity Score26,27 using claims 
from the 6 months prior to diagnosis. The average 
number of classes of OHAs a patient took during 
the 6-months before diagnosis was included to 
account for differences or potential challenges in 
adherence to OHAs that may exist for different 
levels of polypharmacy. 
Propensity scores were used to reduce the selection 
bias when estimating the effect of a prostate cancer 
diagnosis on a patient’s adherence to his OHAs. 
The propensity score model included covariates 
noted previously. This study used the greedy match 
propensity score method that randomly selects a 
case patient with a prostate cancer diagnosis and 
then finds the control patient whose propensity 
score is closest (from the first step) to that of the 
selected case using 1:1 matching. This matching 
process is continued without replacement28 until 
no more viable matches are possible.29-31 To test 
the adequacy of this matching method, boxplots 
were produced to test common support and 
cumulative distributions were compared for each 
continuous variables to test for balance after the 
propensity scores were created. 
This study used interrupted time series analyses in 
which the diagnosis of prostate cancer was 
considered the interruption.32 Adherence to OHAs 
was measured from monthly prescription fills from 
6 months before (pre-period) through the 2 years 
after (post-period) being diagnosed with prostate 
cancer.33 A supply tracker was created for each 
patient that tracked all OHAs in the patients’ 
possession (determined by fill days) for every day 
of the study period; these individual-level diaries 
allowed us to define consecutive fills by drug class 
for each patient-day for days’ supply and 
dispensing date.23,34 
Segmented regression analysis (SRA) was used to 
test the effect of a prostate cancer diagnosis OHA 
adherence using the following equation: 
Yt = B0+B1period2t +B2period3t +B3period4t + 
+B4period5t + B6case + B7case*period2t + 
B8case*period3t + B9case*period4t + 
B10case*period5t + et 
Yt represents being adherent (>80% PDC). Four 
post-period variables were used for each six-month 
period, with the pre-diagnosis period (months 1–6) 
serving as the referent period. These variables were 
also interacted with a case/control indicator 
(control as the referent category) to examine 
whether there were different time trends for 
adherence. As a sensitivity analysis, PDC was also 
measured as a continuous percentage to see if many 
observations were potentially just below the 80% 
threshold and how this affected the trends in 
adherence and results focusing on time. 
The SRA was used in a generalized estimating 
equation (GEE) to estimate the average effect of 
prostate cancer diagnosis on OHA adherence over 
time among patients diagnosed with prostate 
cancer. The cases and controls were structured for 
comparison in the GEE like a fixed 
effects/difference-in-difference model during five 
consecutive six-month periods beginning with the 6 
months pre-diagnosis (Figure 1). GEEs were used 
to address clustering of observations. Relative risk 
(RR) ratios and 95% confidence intervals (CI) were 
calculated to estimate the effect of the main 
independent variable of interest (time period since 
prostate cancer diagnosis) on the likelihood of 
adherence to OHAs; This study estimated both the 
effect of all patients (relative effect of being a 
cancer survivor on adherence over the time 
periods) as well as stratifying patients with and 
without prostate cancer. 
All data were analyzed using SAS Software 
versions 9.3 (SAS Institute Inc., Cary, NC). The 
study was approved by the University of North 
Carolina at Chapel Hill Institutional Review Board. 
Sensitivity Analysis 
As a sensitivity analysis, PDC was calculated to see 
if patients were adherent to all of their OHAs (as 
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opposed to being adherent to at least 1) during the 
course of the study period. To ensure the most 
efficiently fit model, subsequent analyses using 
combinations of Binomial models with logit link 
functions and exchangeable and independent 
correlation structures were also run; QICs (quasi-
likelihood under the independence model criterion) 
were compared to ensure that results were 
calculated using the best-fit models. The final GEE 
model to calculate the RRs had a binomial 
distribution with a logit-link function and 
exchangeable correlation structure as it had the 
lowest QIC of all models. There was no collinearity 
detected among independent variables through the 
Variance Inflation Factor (VIF). 
Results 
Before matching the cohort consisted of 6,193 
patients (1,798 cases and 4,395 potential controls). 
On average, cases were slightly younger (78.8 vs 
79.4 years), less likely to receive low-income 
subsidies for prescription drugs obtained through 
Medicare Part D (30.5% vs 40.8%), and had a 
higher proportion of patients (76.3% vs 70.4%) 
(Table 1). 
Once propensity scores were calculated, the final 
sample consisted of 3,243 total matched patients 
(there were 9 fewer cases (1,617 patients) than 
controls (1,626 patients) due to those matched case 
patients not meeting both of the medication 
inclusions (at least one fill in the 6 months pre-
diagnosis period as well as a fill in the 3 months 
prior to the study period) when PDC was calculated 
(Table 2). The tests for common support and 
balance both produced plots and distributions 
showing that the matches performed well. Average 
PDC was slightly lower for cases than controls 
(66.1% versus 67.0%) post-match. Adherence 
declined in the months immediately following 
cancer diagnosis among cases and controls. The 
five-period trend found cases having slightly lower 
adherence in the six-month period immediately 
following cancer diagnosis, while adherence was 
slightly higher among controls during this same 
period, with both groups gradually declining over 
the remaining periods (Figure 3). 
Table 3 shows the average adherence among both 
patients with and without prostate cancer both 
across the study period as well as within each of 
the 5 study periods. Patients with prostate cancer 
have overall slightly lower adherence than patients 
without prostate cancer, though their average 
adherence in the period prior to cancer diagnosis is 
higher than that of patients without prostate cancer 
(66.7% versus 62.7%); this trend reverses after the 
first 6 months post-cancer diagnosis for the 
remainder of the study. Table 4 displays the RRs 
on the effect of time since a prostate cancer 
diagnosis on patients’ adherence to their OHAs, as 
well as how this relationship differs between 
patients with and without prostate cancer. While 
cases and controls from Period 2 (months 1-6 post 
cancer diagnosis) were more likely to be adherent 
to their OHAs compared to the pre-cancer 
diagnosis period (RR 1.05, 95% CI: 1.01-1.08, not 
shown) and (RR 1.11, 95% CI: 1.15-1.54), 
respectively, cases were found to have lower 
likelihood of adherence compared to controls in 
Period 2. Cases were less likely to be adherent to 
their medications through the remainder of the 
study period when compared to the control group 
ranging from ~6% in Period 2 to 11% in Period 4. 
Among controls, This study observed an increase 
in likelihood of adherence compared to the pre-
diagnosis period, Period 1, across Periods 2-4 
(ranging from ~11% in Period 2 to~8% in Period 
4). 
Results to the sensitivity analysis found similar 
trends in adherence when considering patients 
adherent when they were adherent to at least 1 drug 
when compared versus being adherent if patients 
were adherent to all drugs. Time was actually 
associated with a slightly larger difference in 
adherence pre- and post-diagnosis when measuring 
adherence to all drugs (for example, average 
adherence decreased from 71.0% to 62.7% among 
cases in the periods directly before and after 
prostate cancer diagnosis). To remain conservative 
is our estimates, This study used the adherence to 
at least one OHA measure for our final analysis. 
Table 1. Descriptive Statistics for Patients Pre- and Post–Cancer Diagnosis, Pre- Propensity Score Match 
  Patients with and without Cancer PRIOR TO PROPENS ITY SCORE MATCH (N=6,193) 
 
 
Case Control p-value 
N=1,798 N=4,395  
Race   p<0.001 
White 76.3% 70.4%  
Black 12.4% 7.6%  
Other 8.0% 14.7%  
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Patients with and without Cancer PRIOR TO PROPENS ITY SCORE MATCH (N=6,193) 
 
 
      Case Control p-value 
     N=1,798 N=4,395  
Unknown 3.3% 7.3%  
Urban/Rural   p=0.875 
Big Metro (> 1 million) 51.0% 51.1%  
Metro (250,000-1 million) 29.6% 28.5%  
Urban (20,000-249,999) 6.8% 6.9%  
Less Urban (2,500-19,999) 10.2% 10.7%  
Rural (<2,500) 2.3% 2.8%  
Unknown 0.0% 0.02%  
SEER Region   p<0.001 
San Francisco 3.0% 3.9%  
Connecticut 4.4% 4.3%  
Detroit 6.1% 3.9%  
Hawaii 1.5% 1.6%  
Iowa 6.9% 5.8%  
New Mexico 3.0% 2.5%  
Seattle 3.2% 3.7%  
Utah 2.1% 1.7%  
Atlanta 2.8% 1.7%  
San Jose 3.2% 3.6%  
Los Angeles 9.1% 12.2%  
Rural Georgia 0.4% 0.4%  
Greater Californ ia 17.5% 21.1%  
Kentucky 7.0% 7.0%  
Louisiana 7.0% 4.9%  
New Jersey 14.7% 12.6%  
Greater Georgia 8.4% 8.1%  
Other 0.0% 1.0%  
Level of Subsidy   p<0.001 
Full 26.1% 35.8%  
Partial 4.4% 5.0%  
None 69.5% 59.3%  
Help in Paying for Rx’s  30.5% 40.8% p<0.001 
Charlson Comorbid ity Score 
(mean, (SD) 
 
1.1 (0.83) 
 
1.2 (1.1) 
 
p<0.001 
Age (mean, (SD) 78.8 (5.5) 79.4 (6.4) p=0.002 
 
Table 2. Propensity Matched Patients With and Without Cancer 
 
Mean 
 
Case 
 
Control 
p-value 
(Chi-Sq test/T-test) 
N(3,862) 1,617 (49.9%) 1,626(50.1%)  
Race   p=0.85 
White 79.2% 80.3%  
Black 12.1% 11.5%  
Other Race 8.4% 7.8%  
Unknown 0.3% 0.4%  
Urban/Rural   p=0.94 
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Big Metro (1 mill+) 50.1% 52.5%  
Metro (250k-1 mill) 29.3% 27.7%  
Urban (20k-<250k) 7.2% 6.3%  
Less Urban (2.5k-<20k) 11.0% 10.9%  
Rural (<2.5k) 2.5% 2.7%  
SEER Region   p=0.90 
San Francisco 2.8% 2.4%  
Connecticut 4.7% 4.9%  
Detroit 5.5% 5.2%  
Hawaii 1.6% 1.5%  
Iowa 7.4% 6.9%  
New Mexico 2.8% 2.5%  
Seattle 3.3% 3.0%  
Utah 2.2% 1.5%  
Atlanta 2.7% 2.3%  
San Jose 3.2% 3.3%  
Los Angeles 9.1% 9.7%  
Rural Georgia 0.4% 0.4%  
Greater Californ ia 16.4% 17.2%  
Kentucky 7.2% 7.4%  
Louisiana 7.2% 5.8%  
New Jersey 14.9% 15.9%  
Greater Georgia 8.7% 9.9%  
Level of Subsidy   p=0.82 
Full 25.7% 26.6%  
Partial 4.5% 4.6%  
None 69.8% 68.8%  
Help 30.2% 32.2% p=0.54 
Charlson Score (mean) 1.07 1.1 p=0.34 
Age (mean) 78.8 79.1 p=0.12 
 
 
Table 3. Average Adherence (PDC > 80%) to OHAs among Patients with and without Prostate Cancer 
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Table 4 Effect of Time on Adherence to Diabetes Medications for Patients With and Without a Prostate Cancer Diagnosis 
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Discussion 
To date, few studies have explored whether 
being diagnosed with cancer interrupted 
medication adherence for their non-cancer chronic 
conditions.
35-37
 This study examined the effect of 
being diagnosed with prostate cancer on 
adherence to OHAs among patients with type 2 
diabetes. Non-metastatic, lower-risk prostate 
cancer is an excellent case study for studying 
survivorship care because it is prevalent and has 
high survival rates; diabetes is important not only 
because of its prevalence but also its morbidity 
and associated health care costs. 
This study hypothesized that patients 
would become less adherent to their OHAs during 
the first year post–prostate cancer diagnosis 
compared to their pre-diagnosis adherence levels, 
however their adherence would return to similar 
rates during the second year after being 
diagnosed. We found that patients diagnosed with 
prostate cancer did have decreased adherence 
when compared with controls in the period 
immediately following cancer-diagnosis; 
however, contrary to our hypothesis, adherence to 
their diabetes medications never returned to pre-
diagnosis levels. A similar decline was observed 
among all stages of prostate cancer patients 
during the 6 months post-diagnosis.
17
 However, 
our current study had a longer follow-up period (2 
years vs. 6 months post– cancer diagnosis) and 
more years of data. In addition, we only included 
patients with non-metastatic prostate cancer, a 
group for whom managing comorbidities would 
be a higher priority than patients with more 
aggressive cancer. The finding that diabetes 
patients diagnosed with a highly survivable cancer 
have decreased adherence to their diabetes 
medications two years after diagnosis is 
concerning. Certainly, primary care physicians 
and oncologists should not necessarily assume 
that their patients with chronic diseases will return 
to their baseline medication adherence levels after 
completing cancer treatments, particularly when 
patients believe controlling their diabetes or other 
chronic conditions is not as necessary as it truly 
is.
38
 Given the morbidity and mortality from non-
cancer chronic conditions, providers should 
actively emphasize the importance of taking all 
medications. 
There are several limitations to our 
study. First, claims data do not account for 
prescriptions filled outside the Medicare D benefit 
(i.e., if patients pay out-of-pocket or have another 
source of prescription coverage). Second, we did 
not include insulin in calculating medication 
adherence because our interest was in patients 
with type 2 diabetes. Only patients with type 2 
diabetes should be prescribed OHAs and an OHA 
(Metformin) is the guideline-recommended first 
line of therapy, not insulin.
22
 Insulin was not 
included because the PDC cannot be reliably 
measured with administrative claims data.
8
 
Excluding insulin in PDC calculations is common 
when using claims data.
8,39,40
 Notably, only 28.4% 
of type 2 diabetes patients are either diet-
controlled or use only insulin
1
 and this percentage 
is smaller in older adults.
41
 Third, we are limited 
to patients covered by SEER; however, the SEER 
registry is demographically representative of U.S. 
patients.
25
 Fourth, we measured adherence as to 
whether patients filled a prescription for at least 
one OHA, which may overestimate adherence for 
the ~29% of patients who took more than one 
OHA at a time. Fifth, although PDC assumes that 
patients are taking all prescriptions as they are 
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prescribed, it is possible that some patients filled 
prescriptions but did not take all of the doses of 
that prescription. Estimating adherence from 
claims is potentially not as accurate a method of 
measuring adherence compared with other 
methods such as the Medication Event Monitoring 
Systems (MEMS), which record every time a 
medication bottle is opened.
6
 Finally, we could 
not determine from claims data due to a lack of 
clinical values and/or physician notes and did not 
control for certain hormonal treatments (such as 
Gonadotropin- releasing hormone (GnRH 
agonists)) that may elevate glucose levels and 
require a change or reduction in OHAs that may 
result in our adherence estimates to be 
underestimated.
42
 
Our study extends previous research in cancer 
survivorship and comorbidities by being one of the 
first to examine how being diagnosed with cancer 
affects medication adherence for OHAs in the two 
years post-diagnosis. Although the goal of this 
research was to look at patients with survivable 
prostate cancer, our findings may serve as the basis 
for studies in other chronic diseases and/or 
different tumor types. This study highlights the 
need for continued vigilance on long-term 
medication adherence for comorbidities. 
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